Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending March 2011. The report details a specific share repurchase transaction executed on March 9, 2011, under authority granted by shareholders at the Annual General Meeting on May 6, 2010.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. It focuses exclusively on capital structure and share repurchase activity.
- Shares Purchased: 725,000 Ordinary shares of 25 pence each.
- Price Range: Highest price paid was 1,194.5 pence per share; lowest price paid was 1,180.5 pence per share.
- Treasury Holdings (Settled): 487,289,284 shares (8.59% of total issued share capital).
- Treasury Holdings (Including Unsettled): 488,914,284 shares (9.43% of total voting rights).
- Shares in Issue (Excluding Treasury): 5,183,691,116 shares.
Material Changes
The primary material change reported is the reduction of outstanding shares through the purchase of 725,000 shares for Treasury. Consequently, the percentage of total voting rights held in Treasury increased to 9.43% when including unsettled purchases.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. The stated intention is to hold the purchased shares in Treasury.
Investor Verification Checklist
- Verify the total number of shares held in Treasury against the company's latest annual report to confirm the 8.59% figure.
- Confirm the total issued share capital to validate the calculation of voting rights percentages.
- Check subsequent filings to determine if the unsettled shares mentioned were fully settled.
- Review the authority limits granted at the May 6, 2010 AGM to ensure this purchase remained within approved parameters.